Wednesday, July 8, 2026

pharma · T Cell Lymphoma · Diabetes Mellitus · CRSP

S.A

S.A is a pharma organization headquartered in San Lorenzo, EU. It trades on NYSE under ticker CRSP. Primary therapeutic focus areas include T Cell Lymphoma, Diabetes Mellitus, Beta-Thalassemia, Sickle Cell Disease, B-cel

San Lorenzo, EU HQ
2011 Founded
50 Employees
Public company Type
CRSP · NYSE Ticker
Company details
Status
Public
HQ
San Lorenzo, EU
Founded
2011
Employees
50
Programs
14
Drugs
8
Patents
65
Clinical program

VCTX211

Phase 1 · other · Diabetes Mellitus

VCTX211 for Diabetes Mellitus is a Phase 1 program (other) at S.A. with 1 ClinicalTrials.gov record(s).

← All S.A. projects Phase 1 other terminated

Internal code VCTX211-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
S.A.
Phase
Phase 1
Modality
other
Indication
Diabetes Mellitus
Status
terminated
Trials
1

Clinical trials